A volunteer participates in the vaccine trial in Oxford, England on July 7. In research published on Monday in the journal Lancet, scientists said that they found their experimental Covid-19 vaccine produced a dual immune response in people aged 18 to 55. Photo: University of Oxford via APA volunteer participates in the vaccine trial in Oxford, England on July 7. In research published on Monday in the journal Lancet, scientists said that they found their experimental Covid-19 vaccine produced a dual immune response in people aged 18 to 55. Photo: University of Oxford via AP
A volunteer participates in the vaccine trial in Oxford, England on July 7. In research published on Monday in the journal Lancet, scientists said that they found their experimental Covid-19 vaccine produced a dual immune response in people aged 18 to 55. Photo: University of Oxford via AP

What happens next, as coronavirus vaccine trials move to a new phase?

  • Teams from China, Britain, the US and Germany have shown their potential products are safe but there’s still a long way to go
  • Broad testing across a diverse range – including elderly and less healthy subjects – is crucial to assessing how a vaccine might work on a population

Topic |   Coronavirus pandemic
A volunteer participates in the vaccine trial in Oxford, England on July 7. In research published on Monday in the journal Lancet, scientists said that they found their experimental Covid-19 vaccine produced a dual immune response in people aged 18 to 55. Photo: University of Oxford via APA volunteer participates in the vaccine trial in Oxford, England on July 7. In research published on Monday in the journal Lancet, scientists said that they found their experimental Covid-19 vaccine produced a dual immune response in people aged 18 to 55. Photo: University of Oxford via AP
A volunteer participates in the vaccine trial in Oxford, England on July 7. In research published on Monday in the journal Lancet, scientists said that they found their experimental Covid-19 vaccine produced a dual immune response in people aged 18 to 55. Photo: University of Oxford via AP
READ FULL ARTICLE